ArticleFrontiers in oncology2022

Lenvatinib as second-line treatment in patients with unresectable hepatocellular carcinoma: A retrospective analysis.

He-Nan Qin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.